Strategic Collaborations Dyno is actively expanding its AI-native biology capabilities through high-profile partnerships, including collaborations with NVIDIA to accelerate therapeutic design workflows. This indicates readiness to engage with suppliers of AI tooling, cloud services, and computational biology platforms to support joint development programs.
AI Platform Growth Recent launches of Dyno Psi-Phi and an open-source agentic protein design suite, plus a curated SDI dataset release, signal a strong emphasis on AI-driven design. This opens opportunities to offer specialized AI/ML services, data annotation, model optimization, and cloud-based compute partnerships.
New Capids and Therapies Introduction of two new AAV capsids and muscle-targeted vectors (Dyno-bn8) at industry gatherings suggests ongoing product expansion and target diversification, presenting chances to pitch manufacturing support, regulatory consulting, and supply chain services for gene therapy vectors.
Open Data & Community Dyno’s open data initiatives and community-driven data releases create potential collaborations for platform licensing, data integration, and ecosystem partnerships with biotech service providers seeking to leverage broader datasets for model training and validation.
Scale Readiness With revenue in the tens of millions and a healthy funding base, Dyno appears poised for scale-up collaborations, including services for clinical trial support, advanced analytics, and AI-enabled workflow tooling that can improve design-to-decision timelines for gene therapy programs.